COMO: Cognition Study With HIV+ Patients (CTNPT 015)
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to contribute evidence towards the potential to improve
cognition in HIV+ individuals experiencing cognitive decline through personalized change in
antiretroviral (ARV) medication. To that end, following a comprehensive evaluation to
identify confounding clinical conditions, study participants will undergo a lumbar puncture
to: (i) measure viral load (at 2 copies/ml); (ii) identify Cerebrospinal Fluid (CSF) genotype
and tropism; and (iii) measure concentration of antiretroviral agents. When indicated from
the CSF analysis, a personalized change in ARV will be implemented. Cognition will be
measured in all at study entry and 6 months later.
Phase:
Early Phase 1
Details
Lead Sponsor:
Marie-Josée Brouillette
Collaborators:
CIHR Canadian HIV Trials Network Fonds de la Recherche en Santé du Québec